win.stat | R Documentation |
Calculate the win statistics for a mixture type of outcomes including time-to-event outcome, continuous outcome and binary outcome.
win.stat(data, ep_type, Z_t_trt = NULL, Z_t_con = NULL, iptw.weight = NULL,
arm.name = c(1,2),priority = c(1,2), alpha = 0.05, digit = 5, tau = 0,
np_direction = "larger", win.strategy = NULL,pvalue = c("one-sided","two-sided"),
stratum.weight = c("unstratified","MH-type","wt.stratum1","wt.stratum2","equal"),
method = c("unadjusted","ipcw","covipcw","iptw"),
summary.print = TRUE, ...)
data |
The analysis dataset which contains the following variables:
|
ep_type |
A vector for the outcome type for each endpoint. If scalar, the function will treat all the endpoints as the same type. The types of outcome include:
|
Z_t_trt |
A matrix of the covariate history in the treatment group, each row is a (p+2) vector: the first two columns are subject id, time, the other p columns are the covariates (vector of length p). The baseline covariates are provided as the observed covariates corresponding to time 0. |
Z_t_con |
A matrix of the covariate history in the control group, each row is a (p+2) vector: the first two columns are subject id, time, the other p columns are the covariates (vector of length p). The baseline covariates are provided as the observed covariates corresponding to time 0. |
iptw.weight |
The weight assigned to each individual if method = "iptw". |
arm.name |
A vector for the labels of the two experimental arms, default to be c(1,2). The first label is for the treatment group, and the second label is for the control group. |
priority |
Importance order (from the most to the least important). For example, given three endpoints with the importance order as Endpoint 3, Endpoint 2, and Endpoint 1, input priority = c(3,2,1). |
alpha |
The significance level, default to be 0.05. |
digit |
The number of digits for the output, default to be 5. |
tau |
A vector of numerical value for the magnitude of difference to determine win/loss/tie for each endpoint. Tau is applicable for TTE endpoints and continuous endpoints; tau is fixed as 0 for binary endpoints. Default is 0 for all endpoints. |
np_direction |
A vector of character for the direction to define a better result for each endpoint.
|
win.strategy |
The strategy to determine the win status. Default as NULL. If NULL, the default win strategy funtion "win.strategy.default" is called, see win.strategy.default for more details. Users can also define their own "win.strategy" function. |
pvalue |
The p-value type: "one-sided" or "two-sided". |
stratum.weight |
The weighting method for each stratum. Default is "unstratified" for unstratified analysis. A stratified analysis is performed if other weight option is specified. Other possible choices for this argument are listed below.
|
method |
The method to adjust the kernal functions. Possible choices are listed below.
Other methods may be added in future versions. |
summary.print |
If TRUE, print out a summary of the estimation and inference result for the win statistics; If FALSE, return a list that summarizes the results. Default as TRUE. |
... |
Argument passed from user defined functions "win.strategy" if there is any. For instructions on this "win.strategy" function, see win.strategy.default for more details. |
The arguments of user defined "win.strategy" function must at least include the argument "trt_con" and "priority". "priority" is defined the same as stated in the main function "win.stat". The intermediate analysis dataset "trt_con" for the patient pairs (i.e., unmatched pairs, see Pocock et al., 2012) contains the following variables. Each row represents a pair.
A vector for the stratum number of the unmatched pairs.
A vector for the subject id of the individuals from the treatment group within each unmatched pair.
A vector for the subject id of the individuals from the control group within each unmatched pair.
A vector for the event status of the j-th endpoint (1=event, 0=censored) for the individuals from the treatment group in each unmatched pair. If the outcome type for the endpoint is continuous/binary, then the event status is 1 for all.
A vector for the event status of the j-th endpoint (1=event, 0=censored) for the individuals from the control group in each unmatched pair. If the outcome type for the endpoint is continuous/binary, then the event status is 1 for all.
A vector for the outcome of the j-th endpoint for the individuals from the treatment group in each unmatched pair. For a time-to-event outcome, it would be a vector of observed time-to-event observations.
A vector for the outcome of the j-th endpoint for the individuals from the control group in each unmatched pair. For a time-to-event outcome, it would be a vector of observed time-to-event observations.
Win_prop |
The win proportion of the treatment and the control group. |
Win_statistic |
The win statistics including:
|
z_statistic |
The z-scores including:
|
pvalue |
The p-value for the test statistics including:
|
summary_ep |
The win count and win proportion of the treatment and the control group for each endpoint |
Bebu, I. and Lachin, J.M., 2016. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. Biostatistics.
Buyse, M., 2010. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Statistics in medicine.
Cui, Y., Dong, G., Kuan, P.F. and Huang, B., 2022. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials. Journal of Biopharmaceutical Statistics.
Dong, G., Li, D., Ballerstedt, S. and Vandemeulebroecke, M., 2016. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components. Pharmaceutical statistics.
Dong, G., Qiu, J., Wang, D. and Vandemeulebroecke, M., 2018. The stratified win ratio. Journal of biopharmaceutical statistics.
Dong, G., Huang, B., Chang, Y.W., Seifu, Y., Song, J. and Hoaglin, D.C., 2020. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards. Pharmaceutical statistics.
Dong, G., Mao, L., Huang, B., Gamalo-Siebers, M., Wang, J., Yu, G. and Hoaglin, D.C., 2020. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring. Journal of biopharmaceutical statistics.
Dong, G., Hoaglin, DC., Qiu, J., Matsouaka, RA., Chang, Y., Wang, J., Vandemeulebroecke, M., 2020. The win ratio: on interpretation and handling of ties. Statistics in Biopharmaceutical Research.
Dong, G., Huang, B., Wang, D., Verbeeck, J., Wang, J. and Hoaglin, D.C., 2021. Adjusting win statistics for dependent censoring. Pharmaceutical Statistics.
Dong, G., Huang, B., Verbeeck, J., Cui, Y., Song, J., Gamalo-Siebers, M., Wang, D., Hoaglin, D.C., Seifu, Y., Mutze, T. and Kolassa, J., 2022. Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes. Pharmaceutical Statistics.
Dong, G., Hoaglin, D.C., Huang, B., Cui, Y., Wang, D., Cheng, Y. and Gamalo-Siebers, M., 2023. The stratified win statistics (win ratio, win odds, and net benefit). Pharmaceutical Statistics.
Finkelstein, D.M. and Schoenfeld, D.A., 1999. Combining mortality and longitudinal measures in clinical trials. Statistics in medicine.
Finkelstein, D.M. and Schoenfeld, D.A., 2019. Graphing the Win Ratio and its components over time. Statistics in medicine.
Luo, X., Tian, H., Mohanty, S. and Tsai, W.Y., 2015. An alternative approach to confidence interval estimation for the win ratio statistic. Biometrics.
Pocock, S.J., Ariti, C.A., Collier, T.J. and Wang, D., 2012. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. European heart journal.
Wang D, Pocock S., 2016. A win ratio approach to comparing continuous non-normal outcomes in clinical trials. Pharmaceutical Statistics.
Wang, D., Zheng S., Cui, Y., He, N., Chen, T., Huang, B., 2023. Adjusted win ratio using inverse probability treatment weighting (IPTW) propensity score analysis. Journal of Biopharmaceutical Statistics.
Zheng S, Wang D, Qiu J, Chen T, Gamalo M., 2023. A win ratio approach for comparing crossing survival curves in clinical trials. Journal of Biopharmaceutical Statistics.
#### An example with time-to-event outcome.
head(data_tte)
head(Z_t_trt)
### CovIPCW adjustment for dependent censoring
res_tte_covipcw <- win.stat(data = data_tte, ep_type = "tte", arm.name = c("A","B"), tau = 0.1,
Z_t_trt = Z_t_trt, Z_t_con = Z_t_con, priority = c(1:3), alpha = 0.05, digit = 3,
method = "covipcw", stratum.weight = "unstratified", pvalue = "two-sided")
#### An example with continuous outcome.
head(data_continuous)
res_continuous <- win.stat(data = data_continuous, ep_type = "continuous", arm.name = c("A","B"),
tau = 0, priority = c(1:3), alpha=0.05, digit = 3, stratum.weight = "unstratified",
pvalue = "two-sided")
#### An example with binary outcome.
head(data_binary)
res_binary <- win.stat(data = data_binary, ep_type = "binary", arm.name = c("A","B"),
priority = c(1:3), alpha=0.05, digit = 3, stratum.weight = "unstratified",
pvalue = "two-sided")
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.